Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder (Q33301235)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder |
scientific article |
Statements
1 reference
Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder (English)
1 reference
Stephen M Stahl
1 reference
Marcia F T Rupnow
1 reference
Andrew Greenspan
1 reference
Georges M Gharabawi
1 reference
Colette Kosik-Gonzalez
1 reference
Young Zhu
1 reference
1 November 2007
1 reference
1 reference
Identifiers
1 reference